PCYT2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-5: Human fetal liver tissue, HepG2, A172, Hela and Jurkat cell lysates, Primary antibody: P10138(PCYT2 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P10138(PCYT2 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P10138(PCYT2 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

**Background of PCYT2 Antibodies**

PCYT2 (phosphate cytidylyltransferase 2) is a key enzyme in lipid metabolism, catalyzing the rate-limiting step in the synthesis of phosphatidylcholine (PC) and phosphatidylethanolamine (PE), essential phospholipids for cellular membrane integrity and signaling. The PCYT2 gene encodes the enzyme ethanolamine-phosphate cytidylyltransferase, which converts phosphoethanolamine to CDP-ethanolamine, a critical precursor in PE biosynthesis. Dysregulation of PCYT2 has been implicated in metabolic disorders, neurodegenerative diseases, and cancer, highlighting its role in maintaining lipid homeostasis.

Antibodies targeting PCYT2 are vital tools for studying its expression, localization, and function in various tissues and disease models. These antibodies enable detection of PCYT2 protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research into its regulatory mechanisms and interactions. For instance, studies using PCYT2 antibodies have revealed its involvement in hepatic steatosis, neural development, and tumor progression.

Recent advancements in antibody specificity and validation have improved the reliability of PCYT2 detection, though challenges remain due to potential cross-reactivity with homologous proteins or splice variants. Researchers often validate these antibodies using knockout cell lines or tissues to confirm target specificity. Commercial PCYT2 antibodies are typically raised against peptide sequences unique to the human or murine protein, ensuring species compatibility. Continued development of high-affinity, well-characterized PCYT2 antibodies will further elucidate its pathophysiological roles and therapeutic potential in lipid-related diseases.